Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Microbot Medical. The associated price target remains the same with $12.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju’s rating is based on several strategic and financial factors that position Microbot Medical favorably in the market. The company has recently launched its LIBERTY system, the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures, in a limited market release in the U.S. This strategic move is aimed at gathering real-world insights from high-volume users to ensure a successful full market release in 2026. The potential addressable market for LIBERTY is significant, with approximately 2.5 million procedures annually in the U.S., and the company is well-capitalized to support its full launch.
Additionally, Microbot Medical has strengthened its intellectual property portfolio with a recent patent grant in Japan, complementing existing patents in the U.S., China, and Israel. This robust IP strategy is expected to protect and enhance the company’s market position globally. The valuation of Microbot Medical, with an estimated market value of $848 million and a price target of $12 per share, reflects confidence in the company’s growth prospects. However, potential risks such as slower market uptake and competitive pressures are noted, but the overall outlook remains positive, justifying the Buy rating.